AR074391A1 - Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral - Google Patents

Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral

Info

Publication number
AR074391A1
AR074391A1 ARP090104496A ARP090104496A AR074391A1 AR 074391 A1 AR074391 A1 AR 074391A1 AR P090104496 A ARP090104496 A AR P090104496A AR P090104496 A ARP090104496 A AR P090104496A AR 074391 A1 AR074391 A1 AR 074391A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
powerful
oral administration
Prior art date
Application number
ARP090104496A
Other languages
English (en)
Inventor
Maria Fernanda Villagra
Juan Francisco Gel
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41650279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR074391A1 publication Critical patent/AR074391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica líquida caracterizada porque comprende (a) el compuesto de fórmula (1), o su sal farmacéuticamente aceptable; (b) al menos un tensioactivo; y (c) al menos un disolvente farmacéuticamente aceptable; y en el que la composición está sustancialmente libre de lípidos. Reivindicación 3: Una composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque el tensioactivo es la Vitamina E TPGS , un aceite de ricino polietoxilado, un aceite de ricino hidrogenado de polioxilo, un éster graso de polioxietilen-sorbitan, un macrogolglicérido de caprilocaproilo o sus mezclas. Reivindicación 4: Una composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque el disolvente farmacéuticamente aceptable es propilenglicol, polipropilenglicol, polietilenglicol, glicerol, etanol, triacetin, dimetil isosorbida, glicofurol, carbonato de propileno, agua, dimetil-acetamida o sus mezclas. Reivindicación 6: Una composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque la composición farmacéutica no contiene ningún lípido. Reivindicación 7: Una composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque la composición farmacéutica está sustancialmente libre de propilenglicol. Reivindicación 9: Una composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque el compuesto de fórmula (1) o sus sales farmacéuticamente aceptables comprenden de 1% a 40% en peso de la composición total.
ARP090104496A 2008-11-21 2009-11-20 Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral AR074391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11678908P 2008-11-21 2008-11-21

Publications (1)

Publication Number Publication Date
AR074391A1 true AR074391A1 (es) 2011-01-12

Family

ID=41650279

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104496A AR074391A1 (es) 2008-11-21 2009-11-20 Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral

Country Status (35)

Country Link
US (2) US20120101049A1 (es)
EP (1) EP2358355B1 (es)
JP (1) JP5553839B2 (es)
KR (1) KR20110087297A (es)
CN (1) CN102223875A (es)
AR (1) AR074391A1 (es)
AU (1) AU2009316755B2 (es)
BR (1) BRPI0921070A2 (es)
CA (1) CA2738732A1 (es)
CL (1) CL2011000878A1 (es)
CO (1) CO6361900A2 (es)
CY (1) CY1114892T1 (es)
DK (1) DK2358355T3 (es)
EA (1) EA022272B1 (es)
EC (1) ECSP11011065A (es)
ES (1) ES2445516T3 (es)
HR (1) HRP20140097T1 (es)
IL (1) IL211832A (es)
MA (1) MA32812B1 (es)
ME (1) ME01614B (es)
MX (1) MX2011005151A (es)
MY (1) MY155402A (es)
NZ (1) NZ592383A (es)
PE (1) PE20120032A1 (es)
PL (1) PL2358355T3 (es)
PT (1) PT2358355E (es)
RS (1) RS53121B (es)
SG (1) SG171771A1 (es)
SI (1) SI2358355T1 (es)
TN (1) TN2011000258A1 (es)
TW (1) TWI469801B (es)
UA (1) UA105777C2 (es)
UY (1) UY32252A (es)
WO (1) WO2010059667A1 (es)
ZA (1) ZA201102029B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
GEP20146016B (en) 2009-07-07 2014-01-27 Boehringer Ingelheim Int Pharmaceutical composition containing hepatitis c viral protease inhibitor
AP2013006734A0 (en) 2010-09-30 2013-02-28 Boehringer Ingelheim Int Combination therapy for treating HCV infection
KR20130120481A (ko) * 2010-10-08 2013-11-04 노파르티스 아게 술파미드 ｎｓ3 억제제의 비타민 ｅ 제제
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PE20141817A1 (es) 2012-01-12 2014-12-17 Boehringer Ingelheim Int Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
US20150119317A1 (en) * 2012-05-07 2015-04-30 Bristol-Myers Squibb Company Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
EA029088B1 (ru) 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Макроциклические и бициклические ингибиторы вируса гепатита c
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
AU2002351169B2 (en) * 2001-11-26 2007-09-20 Intas Pharmaceuticals Limited Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
CL2004001161A1 (es) * 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
EP1753775B1 (en) * 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors

Also Published As

Publication number Publication date
RS53121B (en) 2014-06-30
KR20110087297A (ko) 2011-08-02
TN2011000258A1 (en) 2012-12-17
PL2358355T3 (pl) 2014-04-30
ES2445516T3 (es) 2014-03-03
ECSP11011065A (es) 2011-06-30
PT2358355E (pt) 2014-01-08
US20150038532A1 (en) 2015-02-05
ME01614B (me) 2014-09-20
UY32252A (es) 2010-06-30
MX2011005151A (es) 2011-05-30
SG171771A1 (en) 2011-07-28
AU2009316755B2 (en) 2015-10-08
TW201023859A (en) 2010-07-01
CA2738732A1 (en) 2010-05-27
CY1114892T1 (el) 2016-12-14
NZ592383A (en) 2012-11-30
EP2358355B1 (en) 2013-11-06
EP2358355A1 (en) 2011-08-24
EA201100795A1 (ru) 2012-01-30
JP5553839B2 (ja) 2014-07-16
IL211832A0 (en) 2011-06-30
MA32812B1 (fr) 2011-11-01
JP2012509336A (ja) 2012-04-19
MY155402A (en) 2015-10-15
DK2358355T3 (da) 2013-12-16
EA022272B1 (ru) 2015-12-30
WO2010059667A1 (en) 2010-05-27
SI2358355T1 (sl) 2014-02-28
PE20120032A1 (es) 2012-02-12
US20120101049A1 (en) 2012-04-26
TWI469801B (zh) 2015-01-21
BRPI0921070A2 (pt) 2019-09-24
CL2011000878A1 (es) 2011-09-02
IL211832A (en) 2015-02-26
AU2009316755A1 (en) 2010-05-27
HRP20140097T1 (hr) 2014-03-14
UA105777C2 (uk) 2014-06-25
CO6361900A2 (es) 2012-01-20
CN102223875A (zh) 2011-10-19
ZA201102029B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
AR074391A1 (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
AR082930A1 (es) Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
ES2616022T3 (es) Composiciones farmacéuticas de curcumina
ES2575549T3 (es) Comprimido de melatonina y métodos de preparación y uso
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
AR077338A1 (es) Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion.
ECSP10010167A (es) Composiciones oftálmicas novedosas
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
CR9587A (es) Derivados de piridazina
HRP20140445T1 (hr) Farmaceutski sastav za inhibitor proteaze virusnog hepatitisa c
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
AR085547A1 (es) Composicion compleja oral que comprende ester del acido graso omega-3 y un inhibidor de la hmg-coa reductasa
AR048891A2 (es) Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
MX354647B (es) Composicion farmaceutica anticonvulsiva transnasal que comprende un anticonvulsivante escasamente soluble.
CU20190046A7 (es) Composición de concentrado orgánico que comprende ácido 2-{[5-{ 3-cloro-2-metil-4-[2-( 4-metilpiperazin-1-il)etoxi]fenil} -6-(4-fluorofenil)tieno[2,3-d]pirimidin-4-il]oxi}-3-(2-{ [2-(2-metoxifenil)pirimidin-4-il]metoxi} fenil)propanoico y, composiciones liposomales que la contienen
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
AR032586A1 (es) Composicion farmaceutica
AR094941A1 (es) Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla
RU2013126259A (ru) Фармацевтическая композиция таксоидов
ES2497667T3 (es) Sistema de emulsificación para usar en cosméticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure